These inhibitors work by inhibiting CDK4/CDK6-dependent phosphorylation of retinoblastoma (Rb), which blocks proliferation by inhibiting the progression of tumor cells from the G1 phase into the S phase of the cell cycle. The gene discussed is CDK4; the disease is neoplasm.